-
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
31 Aug 2025 16:10 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
30 Aug 2025 07:18 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics to Participate in September Investor Conferences
27 Aug 2025 20:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
25 Aug 2025 11:30 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 12:30 GMT
… the trial. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, … has shown that omecamtiv mecarbil increases cardiac contractility … omecamtiv mecarbil, demonstrated a statistically significant effect of treatment with omecamtiv mecarbil …
-
Cytokinetics Names Jim Daly to Board of Directors
20 Aug 2025 11:30 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Aug 2025 20:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: Withdrawn application
31 May 2024 14:36 GMT
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …
-
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2025 Earnings Call Transcript
12 Aug 2025 12:31 GMT
… later-stage clinical trials evaluating omecamtiv mecarbil and CK-586, now called … Phase III clinical trial of omecamtiv mecarbil in patients with symptomatic heart … failure. So they recognize that omecamtiv mecarbil is a potential medical option …
-
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
07 Aug 2025 20:00 GMT
… in Clinical and Translational Science
omecamtiv mecarbil (cardiac myosin activator) Continued … COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure … HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, …